Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
NEW BRUNSWICK, N.J., December 30, 2008 /PRNewswire-FirstCall/ — Johnson & Johnson today announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that…
18:51 More women than men want to quit smoking
New research shows that almost two thirds of Irish smokers want to quit. 63% of people surveyed said they want to give up cigarettes, while a quarter are already trying to drop the habit.
Biovail recalls some lots of Ultram ER: no safety issue; pain set at $7.4M
Biovail Corp. is recalling an unspecified amount of its Ultram extended-release pain medication, citing a “minor” variance in the rate at which the pills dissolve, and saying there is no safety problem.
Bayer sues Abbott, alleging patent infringement
Pharmaceutical and chemical maker Bayer AG has filed a federal lawsuit alleging that drugmaker Abbott Laboratories’ best-selling drug, Humira, infringes on a decade-old Bayer patent.
Actavis Acquires Kadian; Extends Specialty Drug Portfolio in U.S.
Actavis today announced that it has acquired the brand name drug Kadian from King Pharmaceuticals for not more than USD127.5M, based on quarterly sales related milestones, ending 30 June 2010.
Possible Case: Raptiva
2 Patient Deaths from PML Prompts Health Canada Warning
Fewer deportees being sedated for removal
Fewer deportees reportedly have been sedated with powerful medications during their removal from the country by federal immigration officials.
Actavis Acquires Kadian; Extends Specialty Drug Portfolio in U.S.
MORRISTOWN, N.J.–(BUSINESS WIRE)–Dec 30, 2008 - Actavis today announced that it has acquired the brand name drug Kadian® from King Pharmaceuticals for not more than USD127.5M, based on quarterly sales related milestones, ending 30 June…
King Completes Acquisition of Alpharma
Transaction Creates a Leading Specialty Pharmaceutical Company
BRISTOL, Tenn.–(BUSINESS WIRE)–Dec 30, 2008 - King Pharmaceuticals, Inc. (NYSE: KG) today announced the successful completion of the tender offer by King’s wholly-owned subsidiary,…
Biovail Announces Voluntary Recall of Certain Lots of Ultram ER 100mg Tablets
TORONTO–(BUSINESS WIRE)–Dec 30, 2008 - Biovail Corporation today announced a voluntary recall of certain lots of Ultram® ER (extended-release tramadol hydrochloride) 100mg tablets from pharmacies and wholesalers. Biovail is taking this action…